Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Day 3. Our third daily wrap-up features highlights from the key late breaking trials, and some of the most interesting abstracts presented at the meeting. Key Late-Breaking Clinical Trials Covered: • GRAVITAS Trial – Standard versus high dose clopidogrel according to platelet function testing after PCI • TAMARIS Trial – NV1FGF gene therapy on amputation-free survival in critical limb ischemia – Phase 3 randomized double-blind placebo-controlled trial • BASKET PROVE Trial – Late cardiac death and MI associated with late stent thrombosis in large vessel stenting after 1st and 2nd generation drug-eluting compared to bare-metal stents • ACT Trial – Evaluated acetylcysteine for the prevention of contrast-induced nephropathy Highlighted in the video is expert commentary from leaders in cardiology including: • Matthew Price, MD – Director, Cardiac Catheterization Laboratory, Scripps Clinic; Assistant Professor, Scripps Translational Science Institute • William R. Hiatt, MD – Novartis Foundation Endowed Professor for Cardiovascular Research, Department of Medicine, University of Colorado School of Medicine • Marco Valgimigli, MD, PhD – Director, Cath Lab at Azienda Ospedialiero, University of Ferrera, Italy • Otavio Berwanger, MD, PhD – Director, Research Institute, Hospital do Coração, Sao Paulo, Brazil • Clyde Yancy, MD, FACC, FAHA, MACP – Medical Director, Baylor Heart and Vascular Institute • Christopher B. Granger, MD – Professor of Medicine, Duke University Medical Center • Sarwat Chaudhry, MD – Assistant Professor of Medicine, Yale University School of Medicine Check back tomorrow for AHA Scientific Sessions Meetings in Minutes – Day 4.